Unique ID issued by UMIN | UMIN000002428 |
---|---|
Receipt number | R000002856 |
Scientific Title | Evaluation of efficacy to combine transarterial chemoembolization and intrahepatic arterial infusion of DDP-H for hepatocellular carcinoma |
Date of disclosure of the study information | 2009/09/14 |
Last modified on | 2010/11/11 00:04:23 |
Evaluation of efficacy to combine transarterial chemoembolization and intrahepatic arterial infusion of DDP-H for hepatocellular carcinoma
Efficacy of TACE/hepatic arterial infusion of DDP-H combination in HCC
Evaluation of efficacy to combine transarterial chemoembolization and intrahepatic arterial infusion of DDP-H for hepatocellular carcinoma
Efficacy of TACE/hepatic arterial infusion of DDP-H combination in HCC
Japan |
Hepatocellular carcinoma
Gastroenterology |
Malignancy
NO
Cases with hepatocellular carcinoma (HCC), for which transarterial chemoembolization (TACE) is a proper therapeutic indication, are prospectively divided into two groups in random fashion; 1) TACE alone, and 2) TACE and intrahepatic arterial infusion of DDP-H. The efficacy of DDP-H is evaluated based on response rate of TACE, the time to development of intrahepatic metastasis and overall survival.
Efficacy
Exploratory
Explanatory
Phase II
1) Primary endpoint, the time when a classical HCC is confirmed by several imaging modalities in the liver except for the vicinity to the TACE area.
2) Secondary endpoint, allover survival
Tumor markers of AFP, DCP and other serum biochemistries.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is not considered as adjustment factor.
YES
Central registration
2
Treatment
Medicine |
TACE alone
TACE + intrahepatic arterial infusion of DDP-H
15 | years-old | <= |
80 | years-old | >= |
Male and Female
1) A proper indication for TACE according to Japan HCC management guideline
2) Japan integrated stage scores 2 or 3
3) Child-Pugh A or B
4) No active cancers except for HCC
5) Performance status (ECOG) 0, 1 or 2
6) Satisfying following serum biochemistries before therapy
WBC 3,000 /micro litter=<
Platelet 50,000 /micro litter=<
Hb 8.0 g/dl=<
Total bilirubin 3.0 g/dl=>
Creatinine clearance 50ml/min=< (after adjustment to 1.73m2 of body surface area)
7) No anti-cancer treatments affecting the liver except for the RFA target
8) Agreement to be enrolled in a form of informed consent
1) Severe allergic history for iodine and platinum drug
2) Pregnant, possibility of pregnancy, or feeding a baby
3) Vascular involvement Vp3, Vv3 or more
4) Under interferon therapy
5) Other factors that a responsible doctor judged to be unsuitable
160
1st name | |
Middle name | |
Last name | Takeshi Suda |
Niigata University Graduate School of Medical and Dental Sciences
Department of Gastroenterology & Hepatology
1-754 Asahi-machi, Chuo-ku, Niigata, Niigata 951-8122, Japan
025-227-2207
1st name | |
Middle name | |
Last name | Akihiko Ohsaki |
Niigata Hepatocellular Carcinoma Therapy Study Group
Excutive office
1-757 Asahi-machi, Chuo-ku, Niigata, Niigata 951-8122, Japan
025-227-2207
tm98020ao-nii@umin.ac.jp
Niigata Hepatocellular Carcinoma Therapy Study Group
None
Self funding
Japan
NO
2009 | Year | 09 | Month | 14 | Day |
Unpublished
Terminated
2009 | Year | 09 | Month | 01 | Day |
2009 | Year | 09 | Month | 01 | Day |
2013 | Year | 08 | Month | 01 | Day |
2013 | Year | 08 | Month | 01 | Day |
2013 | Year | 08 | Month | 01 | Day |
2015 | Year | 03 | Month | 01 | Day |
2009 | Year | 09 | Month | 01 | Day |
2010 | Year | 11 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002856